Connect with us

Breaking News

US Panel Endorses Covid-19 Vaccine; Campaign Needs FDA Approval

Published

on

Medical doctor holding a Pfizer COVID-19 vaccine vial-US panel endorses Pfizer Covid-19 vaccine, massive campaign now waits FDA approval-ss-featured

An independent panel of experts has overwhelmingly voted to recommend that the Food and Drug Administration (FDA) authorize Pfizer’s Covid-19 vaccine for emergency use in people ages 16 and older. A positive FDA decision will open the door for US citizens to be vaccinated against the disease.

The vote Thursday afternoon was 17 in favor of the authorization and four against, with one person abstaining.

The members of the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, did not receive an opportunity to explain their votes against recommending authorization.

However, there was much discussion before the final vote about authorizing the shots for teenagers 16 and 17 years old. Some experts worried there was not enough data to make an informed decision about the vaccine in adolescents.

Emergency use

In a reaction, the head of the FDA says his agency has told Pfizer that it “will rapidly work” to grant emergency use of its Covid-19 vaccine following a positive recommendation by government advisers.

The FDA decision will kickstart an unprecedented vaccination campaign needed to eventually defeat the virus. The FDA’s greenlight of the vaccine, co-developed with BioNtech, was practically assured after the positive vote by the VRBPAC a day earlier.

The FDA’s brief statement came less than an hour after President Donald Trump tweeted directly at FDA Commissioner Stephen Hahn, complaining that FDA “is still a big, old, slow turtle.”

FDA staff have repeatedly said they expect to issue a decision within days of Thursday’s meeting. Many FDA observers predict action by Saturday ahead of a Sunday meeting by the Centers for Disease Control and Prevention (CDC.)

The panel of CDC advisers will vote on who should get priority for the initial shots. Federal officials also plan to allocate the first 6.4 million doses of the vaccine to states based on their population.

In parallel development, on December 17, the VRBPAC will meet in open session to discuss Emergency Use Authorization of the Moderna, Inc., Covid-19 Vaccine for the prevention of Covid-19 in individuals 18 years and older.

Up Next:

Source: (RFI)

Copyright © 2020 Breaking News Alerts. This copyrighted material may not be republished without express permission. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that this website has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this page and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This website contains advertisements.

[email]
[email]